StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

VNRX has been the topic of a number of other research reports. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a report on Wednesday, April 30th. HC Wainwright began coverage on VolitionRx in a report on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, VolitionRx currently has an average rating of “Hold” and an average price target of $3.33.

VolitionRx Stock Performance

Shares of NYSE VNRX opened at $0.52 on Wednesday. The business has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.60. VolitionRx has a 52 week low of $0.42 and a 52 week high of $0.90. The stock has a market cap of $52.42 million, a price-to-earnings ratio of -1.44 and a beta of 1.00.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds acquired 181,818 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter worth approximately $36,000. Lagoda Investment Management L.P. raised its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Northern Trust Corp lifted its position in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the period. Two Sigma Securities LLC acquired a new stake in VolitionRx during the fourth quarter worth $29,000. Finally, Geode Capital Management LLC increased its holdings in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares during the period. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.